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Many studies have demonstrated that serum gamma glutamyltransferase (GGT) 
within normal range might be an early marker of oxidative stress. However the role of 
GGT in neuromyelitis optica (NMO) and multiple sclerosis (MS) is unknown.  
Methods 
We assessed the correlations among GGT and C-reactive protein (CRP) levels, as 
well as clinical characteristics of NMO and MS. Serum GGT and CRP levels were 
measured in 106 NMO patients, 87 MS patients, 79 patients with non-inflammatory 
neurological diseases (Parkinson disease) and 80 healthy controls (HC). Clinical 
parameters, blood-brain barrier (BBB) index and Delpech index of MS and NMO 
were also investigated.  
Results 
We found that NMO patients had higher serum GGT and CRP levels within their 
normal ranges compared to MS, PD, healthy controls. NMO patients exhibited 
significantly higher EDSS scores than MS patients. The BBB index in NMO patients 
was significantly higher than that in MS patients. Significant correlations existed 





Elevated GGT and CRP levels within their normal ranges in NMO and MS may be 
associated with inflammatory response, oxidative stress and BBB disturbance in the 
diseases. Further study into the underlying pathophysiology of this relationship is 
warranted. 
Abbreviations 
GGT, gamma-glutamyltransferase; CRP, C-reactive protein; MS, multiple sclerosis; 
NMO, neuromyelitis optica; PD, Parkinson disease; EDSS, expanded Disability 
Status Scale; NMO-IgG, neuromyelitis optic-immunoglobulin; AQP4, aquaporin 4; 
BBB, blood-brain barrier. 
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1. Introduction  
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central 
nervous system (CNS) that can cause severe optic neuritis and myelitis (Kira 2011). 
Multiple sclerosis (MS) is also an inflammatory demyelinating disease of the CNS 
(Kira 2003). In Asia, NMO is more common than MS. The distinction between NMO 
and MS has long been unclear. For many decades NMO was considered a variant of 
MS. However some studies have shown that inflammatory NMO profiles primarily 
present as eosinophils/neutrophils and autoantibody reactions (Correale and Fiol 
2004; Weinshenker 2007), whereas MS has T-lymphocyte and mononuclear 
macrophage reactions as the primary immunopathogenesis (Barnett et al. 2006). In 
addition a majority of NMO patients develop auto-antibodies (NMO-IgG) against 
aquaporin 4 (AQP4) in the CNS (Lennon et al. 2004). As a result Weinshenker et al 
suggested that NMO was distinguishable from MS in clinical, imaging, serological, 
and immunopathological profiles (Weinshenker 2003).  
A series of epidemiological studies (Lee et al. 2004; Lee and Jacobs 2005; Lee et 
al. 2003; Lee et al. 2004) have suggested serum gamma glutamyltransferase (GGT) 
within its normal range might be an early marker of oxidative stress. C-reactive 
protein is proven to be a classical marker of inflammation. Lee et al (Lee and Jacobs 
2005) argued that oxidative stress leads to an inflammatory response and elevation in 
GGT might occur before elevation in CRP. CRP values were similar in patients with 
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MS and in healthy controls but higher during MS relapses than in remission 
(Soilu-Hanninen et al. 2005). 
Although the relationship between cellular GGT and serum GGT is not known, 
cellular GGT has been known to play an important role in antioxidant defense 
systems (Kugelman et al. 1994). Paradoxically, cellular GGT may also be involved in 
the generation of reactive oxygen species in the presence of transition metals (Drozdz 
et al. 1998; Glass and Stark 1997) and glutathione metabolized by GGT initiates an 
oxidative process that leads to a radical-rich environment and oxidative damage 
(Stark et al. 1994). In addition GGT expression regulates reactive oxygen species 
(ROS) in T-lymphocytes and modulates Fas-induced damage by altering NF-kappa B 
activity (Carlisle et al. 2003). As we know, oxidative stress appears to be a key 
component of many reactions associated with chronic inflammation, and chronic 
oxidative stress is thought to result in damage to DNA, lipids, proteins, and other 
molecules which may contribute to the development and progression of chronic 
diseases including diabetes (Xu et al. 2011), cardiovascular disease (Holvoet et al. 
2007), cancer (Strasak et al. 2008), MS (Gonsette 2008a, b), and NMO (Penton-Rol et 
al. 2009). Previous studies have shown that serum GGT level was increased in some 
chronic diseases such as diabetes (Lee et al. 2003), cardiovascular disease (Lee et al. 
2007) and cancer (Strasak et al. 2008). However little is known about GGT and CRP 
levels in idiopathic inflammatory CNS diseases such as NMO and MS. The present 




2. Methods  
2.1  Study subjects 
The present study was performed at the MS Clinical Center, Department of 
Neurology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. 
China. From 2007 to 2011, serum samples were collected from 352 participants. In 
order to investigate serum GGT levels in patients with non-inflammatory neurological 
disorders we also enrolled Parkinson disease (PD) patients as a control group. 
Demographic and clinical characteristics of NMO and MS patients, as well as PD 
patients and healthy controls are presented in Table 1. MS was identified in 
accordance with McDonald’s criteria (Polman et al. 2005), and NMO was defined 
according to Wingerchuk’s criteria (Wingerchuk et al. 2006). All patients were scored 
using the Expanded Disability Status Scale (EDSS).  
 
2.2  Ethics Statement 
The present study’s protocol was approved by the Ethics Committee of the Third 
Affiliated Hospital of Sun Yat-sen University (No.2007-33), and all participants 
involved in this study provided written informed consent. Consent was given both in 
writing and verbally for measuring the Expanded Disability Status Scale (EDSS) 
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scores and all measurements were performed by an experienced neurologist who was 
blinded to the diagnostic categorization. The measurement procedure was taken as 
defined by Kurtzke (Kurtzke 1983). Since those measurements benefit the therapies of 
NMO and MS patients involved in this study, the ethics committees also approved 
this consent procedure.  
 
2.3  Anti-AQP4 antibody serum testing 
Serum from 111 NMO patients was tested for the presence of anti-AQP4 antibodies 
using a commercial sampling kit (Euroimmun, Lübeck, Germany) in accordance with 
the manufacturer’s instructions.  
 
2.4  Blood-brain barrier (BBB) index and Delpech index 
Samples of cerebral spinal fluid (CSF) and matched serum were obtained from MS 
patients and NMO patients. Three MS patients refused lumbar puncture. The 
concentrations of IgG and albumin (Alb) in paired serum and CSF were measured by 
nephelometry, and the BBB index and Delpech index were calculated according to the 
following formulas: BBB index formula=1000 Alb csf/Alb serum and Delpech index 




2.5  Biochemical measurements 
Serum GGT level and CRP level were measured using an autoanalyser (Clinical 
Analyzer 7180-ISE, Hitachi High Technologies, Tokyo, Japan). Venous blood 
samples for serum GGT measurements were obtained from all subjects. Levels of 
serum GGT ﹥50U/L were determined to be above laboratory pathology cutpoint in 
our hospital. Levels of serum GGT ﹥50U/L, and alanine transaminase (ALT) ﹥45 
U/L were determined to abnormal liver function. 
Exclusion criteria included treatment with acetylsalicylic acid, thiazide diuretics, 
ibuprofen, and other drugs that could influence liver enzyme levels, as well as 
subjects with diabetes or liver, heart, or renal disease and alcohol intake. All samples 
were taken before intravenous methylprednisolone (IVMP). Fulfillment of inclusion 
and exclusion criteria was confirmed retrospectively by a review of medical records 
by the neurologist specialized in demyelinating diseases. 
 
2.6  Statistical analysis 
All continuous variables were presented as the mean (± standard deviation) if the data 
was normally distributed or as medians (min, max) if the data was not normally 
distributed. The categorical variable (gender) was shown as a percentage. The effect 
of age on serum GGT levels for different groups was analyzed by covariance analysis. 
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The comparison between serum GGT levels of the NMO, MS, PD, and healthy 
control subjects was performed using covariance analysis with age as the covariant. 
Since serum GGT level has been shown to be dependent on gender, patients within 
each group were divided into two subgroups according to gender. In order to compare 
serum GGT levels in NMO patients with anti-AQP4 antibody seropositive and with 
anti-AQP4 antibody seronegative, we also used covariance analysis with age and 
gender as the covariant. A Spearman’s rank correlation coefficient was used to 
evaluate the association of age, disease duration, annualized relapse rate, EDSS score 
and serum GGT level in NMO and MS patients. SPSS 16.0 (Chicago IL, USA) was 




Mean EDSS scores in the NMO group were significantly higher than in the MS group 
(3.8 vs 2.9, P < 0.001, Table 1). No significant differences were detected in age, 
disease duration, or annualized relapse rates between the MS and NMO groups. There 
were significant differences in annualized relapse rates between AQP4-seropositive 
NMO patients and AQP4-seronegative NMO patients, and serum GGT levels and 
BBB index in seropositive NMO-IgG NMO were higher than that in seronegative 
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NMO-IgG NMO patients, however the differences were not statistical significant 
(Table 2).  
Serum GGT levels and CRP were significantly higher in NMO patients than that in 
MS, PD and healthy controls (Figure. 1A, C; Table 1). And serum GGT and CRP 
were also higher in MS than that in PD, healthy controls, but the differences were not 
significant. And the differences of serum ALT within normal range between NMO, 
MS, PD and healthy controls were not significant (Figure 1B). 
In order to compare the BBB integrity in NMO and MS groups, we investigated the 
BBB index and Delpech index. The BBB index in the NMO group was significantly 
higher than that in the MS group (6.50 ± 4.41 vs 5.33 ± 3.03, p=0.038, Figure 
2A), and the Delpech index in the NMO group was also higher than that in the MS 
group, however the difference was not statistically significant (0.54 ± 0.38 vs 0.46 
± 0.21, p=0.108) (Figure 2B). 
Furthermore, serum GGT and CRP levels were significantly higher in female NMO 
patients than in female MS patients, female PD patients or female healthy controls 
(Figure. 3A, B), serum GGT and CRP levels were significantly higher in male NMO 
patients than that in male PD. However there was no significant difference in GGT 




In NMO patients there was a significant correlation between serum GGT levels and 
CRP level (rs =0.502, p<0.001, Figure 4A), EDSS scores (rs = 0.532, p<0.001, Figure 
4B), BBB index (rs = 0.585, p<0.001, Figure 4C), age (rs = 0.359, p < 0.001, Figure 
4D), but no significant correlations between GGT levels and annualized relapse rate, 
disease duration or Delpech index. In MS patients there was significant correlation 
between serum GGT levels and CRP level (rs = 0.221, p =0.04, Figure 4E), EDSS 
score (rs = 0.310, p =0.004, Figure 4F), BBB index (rs = 0.391, p <0.001, Figure 4G), 
disease duration (rs = 0.234, p = 0.029, Figure 4H), but correlations between GGT 
level and age, annualized relapse rate, or Delpech index were not significant.  
 
4. Discussion 
In the present study EDSS scores were significantly higher in NMO patients 
compared to MS patients as a result of more severe blindness and paralysis. This was 
reflected by more severe disability in NMO which was consistent with previous 
studies (Li et al. 2010; Weinshenker 2007). 
 GGT is a well-established serum marker for liver disease. However, elevated 
GGT is associated to increased risk to a multitude of diseases and conditions, 
including cardiovascular disease, diabetes, metabolic syndrome (MetS) and so on 
(Goldberg 2010; Koenig and Seneff 2015). Elevated GGT levels could lead to 
prooxidant activity, particularly in the presence of iron or copper (Milnerowicz et al. 
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2014; Corti et al. 2009). Furthermore, elevated GGT levels could damage to red blood 
cell membranes, then caused the release of these potentially toxic transition metals, 
which could further result in chain, prooxidant reactions (Aberkane et al. 2002). And 
increased prooxidation levels can contribute to downstream cell, tissue, and DNA 
damage caused by oxidative and nitrosative stress and the generation of deleterious 
reactive oxygen species or nitric oxide (Stefano and Kream 2015). Therefore, GGT is 
a marker of oxidative stress, and an elevated serum GGT level within normal range is 
thought to be associated with and oxidative stress and inflammation (Koenig and 
Seneff 2015; Lee and Jacobs 2005, 2015; Lee et al. 2008). Similarly, increased 
plasma CRP is correlated with myocardial infarction, PD, MS, and ischemic stroke 
(Soilu-Hanninen et al. 2005; Zhang et al. 2011; Kjaergaard et al. 2010). In the present 
paper, serum GGT and CRP levels were higher in patients with NMO and MS than 
that in patients with PD and healthy controls. And we also found serum GGT were 
positively associated with CRP, BBB index in NMO and MS patients. The results 
demonstrate that the elevated serum GGT and CRP may be associated with oxidative 
stress and inflammatory response in NMO and MS. Therefore we inferred that 
elevated serum GGT within normal range could serve as a marker for more oxidative 
and inflammatory stress and severe BBB destruction in NMO and MS. 
Furthermore, NMO patients have significantly higher GGT level and BBB index 
than that in MS. Many studies have shown that oxidative reactions and inflammatory 
profiles in NMO patients are different from MS patients (Correale and Fiol 2004; 
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Gonsette 2008a; Weinshenker 2007; Wingerchuk and Lucchinetti 2007). In addition 
the mechanism of blood-brain barrier (BBB) destruction in NMO patients may differ 
from that in MS patients (Lennon et al. 2004; McQuaid et al. 2009; Minagar and 
Alexander 2003; Pittock et al. 2006; Vincent et al. 2008). The BBB index, which may 
reflect BBB destruction, was significantly higher in the NMO patients than that in the 
MS patients in our present study. On the other hand, many previous studies have 
shown that GGT, which was known as a marker for BBB function, played an 
important role in maintaining BBB integrity (Beuckmann et al. 1995; Kuchler-Bopp 
et al. 1999; Meyer et al. 1991; Ramsauer et al. 1998). Our results suggested that an 
elevated serum GGT level within normal range in NMO patients may reflect more 
severe oxidative and inflammatory reactions, as well as BBB dysfunction in NMO 
patients.  
Aquaporin 4 (AQP4) is a water channel expressed by astrocytes and is localized at 
astrocyte footpads adjacent to endothelial cells, and exerts effects on the BBB. Some 
studies have suggested that anti-AQP4 antibodies (NMO-IgGs) might participate in 
pathogenic mechanisms of BBB dysfunction in NMO (Lennon et al. 2004; Pittock et 
al. 2006; Vincent et al. 2008). NMO-IgGs exhibit functional effects on cellular 
components of the neurovascular unit and also promote BBB opening and granulocyte 
recruitment in NMO (Vincent et al. 2008). In our study, we found annualized relapse 
rate in seropositive NMO-IgG NMO patients was significantly higher than that in 
seronegative NMO-IgG NMO patients, suggested that seropositive NMO-IgG NMO 
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patients may more likely to relapse. And serum GGT levels and BBB index in 
seropositive NMO-IgG NMO were higher than that in seronegative NMO-IgG NMO 
patients, though differences were not statistical significant. 
In the present study we also found serum GGT and CRP levels were significantly 
higher in female NMO patients than in female MS, PD patients or female healthy 
controls. And female MS had higher GGT levels than that in female healthy controls. 
Correlation was measured to determine the association between clinical variables 
and serum GGT and CRP in NMO patients. First, serum GGT was significantly 
positively associated with CRP in NMO, MS. This was compatible with the 
hypothesis that GGT was associated with the inflammatory response. Second, serum 
GGT levels and CRP level both had significant correlation with EDSS and BBB index 
in NMO and MS patients. We speculated that serum GGT and CRP might be 
associated with the BBB destruction, progression and outcome in NMO and MS 
patients.  
To the best of our knowledge, this is the first study to analyze serum GGT levels in 
NMO and MS patients. However several limitations existed in the study. Firstly, the 
sample size was relatively small [NMO (n = 106), MS (n = 87), PD (n= 79) and 
healthy controls (n = 80)]. Secondly, biases are difficult to prevent with retrospective 
studies. Thirdly, the major limitation of this report is the fact that it is essentially an 
initial observational exploratory study without corroborating experimental evidence. 
 
15 




Results from the present study suggested that serum GGT and CRP levels were 
elevated within their normal ranges in NMO and MS patients versus controls. We 
speculated that elevated serum GGT and CRP level within their normal ranges may be 
associated with the inflammatory response, oxidative stress and BBB destruction in 
NMO and MS patients. Further studies regarding the role of GGT in NMO and MS 
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Figure 1 Serum GGT, ALT, CRP level in NMO and MS patients, PD patients, as 
well as healthy controls. A. Serum GGT level in NMO patients was significantly 
higher than in MS patients, PD patients, healthy controls respectively. Serum GGT 
level in MS patients was not significantly higher than in PD patients and healthy 
controls. Values represent mean ± SD. B. The differences of serum ALT levels 
between NMO, MS, PD and health controls were not significant. Values represent 
mean ± SD. C. Serum CRP in NMO levels were significantly higher than that in MS, 
PD and controls. Values represent median with range. 
*
p < 0.5, 
**




Figure 2 BBB index and Delpech index in NMO and MS. The BBB index in the 
NMO group was significantly higher than that in the MS group (Figure 2A), and the 
Delpech index in the NMO group was also higher than that in the MS group, 
however, the difference was not statistically significant (Figure 2B). Values represent 
mean ± SD. 
Figure 3 Serum GGT level and CRP in male and female NMO, MS, PD, and 
healthy controls. A. In the female cohort, serum GGT levels in NMO patients were 
significantly greater than that in MS, PD and healthy controls respectively. And serum 
GGT levels in female MS patients were significantly higher than that in female 
healthy controls. Values represent mean ± SD. B. In female cohort, serum CRP levels 
were significantly higher in NMO than that in MS, PD and health controls. Values 
represent median. 
*
p < 0.5, 
**
p < 0.01, 
*** 




Figure 4. Association between serum GGT and CRP, EDSS and BBB index in 
NMO and MS patients. ABCD, serum GGT levels versus CRP level. EDSS scores, 
BBB index, age in NMO patients. EFGH, serum GGT levels versus CRP level, EDSS 
score, BBB index, disease duration in MS patients.  
 
 
Table 1 Demographic and clinical parameters of NMO, MS, PD and Healthy controls 
Clinical parameters NMO (n 
= 106) 
MS (n = 
87) 
PD (n = 
79) 
HC (n = 
80) 
p 




33 (41.2) - 











Disease  Duration 
(months, median, 
range) 
18 (0.1 - 
240) 
12 (0.2 - 
420) 
60 (4 - 
180) 
- 0.697 
Annualized relapse rate 
(median, range) 
2 (1 - 12) 2 (1 - 
13) 
- - 0.805 
EDSS scores (mean, 
range) 
3.8 (1 - 
8.5) 
2.9 (0 - 
9.5) 
- - 0.005 
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(10 - 50) 
0.011 









(10 - 44) 
0.978 
Serum CRP level 
(mg/L, median, range) 
1.85 (0 - 
21.2) 
1 (0 - 
19.6) 
0.9 (0 - 
5) 
0.75 (0 - 
13.3) 
<0.001 
MS, multiple sclerosis; NMO, neuromyelitis optica; PD, Parkinson disease; HC, 
Healthy control, EDSS, expanded disability status scale; GGT, 
gamma-glutamyltransferase; ALT, alanine transaminase; CRP, C-reactive proteins. p: 




Table 2 Comparison of clinical parameters, serum GGT level, and BBB index, 
Delpech index in NMO patients with anti-AQP4 antibody seropositive and with 
anti-AQP4 antibody seronegative 







Age(years, mean±SD) 38.13 ± 13.39 31.83 ± 13.94 0.057 
Disease duration(months, 
median, range) 
24 (0.1 – 240.0) 7.3 (0.1 – 240.0) 0.082 
Annualized relapse rate 
(median, range) 
3 (1 - 12) 2 (1 - 7) 0.03 
EDSS score (mean±SD) 3.7 ± 2.2 4.0 ± 2.5 0.526 
GGT (U/L, mean±SD) 29.37 ± 12.51 28.87 ± 11.22 0.852 
CRP (mg/L, median, 
range) 
1.85 (0 – 21.2) 2.00 (0 – 10.3) 0.916 
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BBB index (median, 
range) 
4.66 (0.37 – 19.43) 4.07 (0.45 – 18.67) 0.514 
Delpech index (median, 
range) 
0.47 (0.16 – 0.95) 0.50 (0.14 – 4.0) 0.564 
GGT, gamma-glutamyltransferase; CRP, C-reactive protein; NMO, neuromyelitis 
optica; EDSS, expanded Disability Status Scale; AQP4, aquaporin 4; BBB, 
























1. This is the first study to analyze serum GGT levels in NMO and MS patients. 
2. Serum GGT and CRP levels were elevated within their normal ranges in NMO 
and MS patients versus controls. 
3. The blood brain-barrier destruction in NMO patients was more severe than that in 
MS patients. 
4. Elevated serum GGT level may be associated with the inflammatory response, 
oxidative stress and BBB destruction in NMO and MS patients. 
 
 
